Tirzepatide for Health & Longevity

Created on 10/31/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Tirzepatide is a once-weekly injectable prescription medication that imitates two gut hormones to curb appetite and improve blood sugar control. In adults with excess fat or early blood sugar problems, strong evidence shows large, lasting fat loss, better blood sugar and lower blood pressure. The main drawbacks are digestive side effects, muscle loss along with fat, gallbladder problems and weight regain after stopping. Slower aging remains unproven. (Full Review)

Protocol

Labeled weight-management regimen (Eli Lilly)
2.5 mg weekly for 4 weeks, then 5 mg
Increasing by 2.5 mg every 4 weeks or more to a maintenance dose of 5, 10, or 15 mg; maximum 15 mg
Single versus split dosing
One subcutaneous injection weekly
Abdomen, thigh, or upper arm, rotating sites; split or more frequent dosing has not been studied
Lower-dose maintenance alternative
5 mg after loss on 10–15 mg
Kept −16.6% versus −21.9% on full dose and −9.9% on placebo at 112 weeks
Time to effect
Weight loss
Over the first months
Most users plateau by 72 weeks (median 24–36 weeks)
Blood pressure
Within 24 weeks
Then stays lower
Appetite
Within days
Gastric emptying slows most after the first doses, fading over later weeks

Benefits

Contraindications
  • Personal or family history of medullary thyroid carcinoma, or MEN 2
  • Prior serious hypersensitivity (anaphylaxis, angioedema) to tirzepatide or its excipients
  • Pregnancy (stopped when recognized)
  • Severe gastroparesis (use not recommended)
  • BMI below 27 kg/m², or below 30 kg/m² without a weight-related condition (no efficacy or safety data)
  • History of pancreatitis (inferred; no human data on recurrence risk)
  • Current eating disorder or underweight state (inferred; no human data)
Key Interactions
  • Insulin and sulfonylureas (glipizide, glimepiride): additive glucose lowering causes hypoglycemia
  • Oral hormonal contraceptives (ethinyl estradiol with norgestimate): contraceptive failure risk
  • Narrow-therapeutic-index oral drugs (warfarin, levothyroxine, lithium): slowed gastric emptying can alter absorption
  • Antihypertensive drugs (lisinopril, amlodipine): additive blood pressure lowering
  • Hydrochlorothiazide in kidney disease: severe hypercalcemia in a case report
  • Other GLP-1 receptor agonists or tirzepatide products (semaglutide, liraglutide): co-administration is not recommended (Avoid)
  • General anesthesia or deep sedation (other intervention): retained gastric contents risk pulmonary aspiration
  • Oral opioids (sustained-release morphine): life-threatening opioid toxicity in a case report
Theoretical (inferred from mechanism)
  • Glucose-lowering supplements (berberine, chromium): additive glucose lowering, hypoglycemia risk mainly with insulin or sulfonylureas
  • Gut-slowing medications (loperamide, diphenhydramine): additive slowing of gut motility
  • Fiber supplements (psyllium, glucomannan): additive fullness and slowed gastric emptying
  • Alcohol: additive hypoglycemia with insulin or sulfonylureas, added pancreatic and dehydration stress
  • Stimulant weight-loss supplements (caffeine, synephrine): additive heart-rate increase
  • Very low-calorie diets or prolonged fasting (other intervention): additive dehydration, lean mass loss, gallstone formation, and hypoglycemia with glucose-lowering drugs

Risk & Side Effects

  • High: Gastrointestinal adverse events, lean mass loss, gallbladder disease, weight regain and loss of cardiometabolic gains after stopping, resting heart rate increase
  • Medium: Hypoglycemia with insulin or sulfonylureas, acute kidney injury from dehydration, low blood pressure and dizziness, hair loss, fatigue, dysesthesia, dry mouth and taste disturbance
  • Low: Hypersensitivity and injection-site reactions, acute pancreatitis, medullary thyroid carcinoma, diabetic retinopathy worsening, optic nerve damage, pulmonary aspiration during anesthesia, bone mineral density loss, ketoacidosis, rhabdomyolysis
  • Speculative: Fetal harm

Monitoring

Marker Target Why
Body weight and waist circumference No established target; track percent change from own baseline Primary response marker
Lean mass and bone density (DXA) No established target; track change from own baseline Safety check for excess lean or bone loss
HbA1c 4.0–5.6% Expected to change; low values with glucose-lowering drugs signal hypoglycemia risk
Fasting glucose 70–99 mg/dL Safety check for hypoglycemia on insulin or sulfonylureas
Blood pressure No established target; track change from own baseline Safety check for hypotension
Lipid panel (LDL, HDL, triglycerides) No established target; track change from own baseline Expected to change modestly
Creatinine with eGFR and urine albumin-to-creatinine ratio Creatinine 0.6–1.3 mg/dL (sex- and laboratory-specific); eGFR and albumin-to-creatinine ratio: no established target; track change from own baseline Safety check for dehydration-related kidney injury
Lipase 0–160 U/L (laboratory-specific) Baseline for interpreting abdominal pain
Heart rate 60–100 beats per minute Tirzepatide raises heart rate 1–3 beats per minute
Calcitonin (only if thyroid concern) Below 10 ng/L (sex- and laboratory-specific) Values above 50 ng/L suggest medullary thyroid carcinoma
Liver enzymes Not specified in the ER Baseline safety reference point
Grip strength Not specified in the ER Paired with DXA to check preserved strength

Cadence: Baseline before starting; weight, blood pressure, and symptoms at each dose escalation (every 4 weeks); kidney function within 1–2 weeks of any vomiting or diarrhea episode; labs at 3 months, then every 6–12 months; DXA at 12 months, then every 1–2 years

Qualitative Assessment

  • Hunger, cravings, and fullness cues
  • Nausea, reflux, constipation, or bowel habit changes
  • Energy, exercise performance, and strength during training
  • Sleep quality and daytime alertness, including snoring or apnea symptoms
  • Hair shedding
  • Mood and relationship with food